Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings e ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Sty ...

Shares of Harmony Biosciences Holdings, Inc. (HRMY) have gained 13.5% over the past four weeks to close the last trading session at $39.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $51 indicates a potential upside of 29%.The average comprises 10 short-term price targets ranging from a low of $28 to a high of $75, with a standard deviation of $13.58. While the lowest estim ...

Core Insights - Harmony Biosciences Holdings, Inc. (HRMY) is currently viewed as a better value opportunity compared to Repligen (RGEN) for investors interested in Medical - Biomedical and Genetics stocks [1] Valuation Metrics - HRMY has a forward P/E ratio of 12.06, significantly lower than RGEN's forward P/E of 99.13 [5] - HRMY's PEG ratio stands at 0.51, indicating a favorable valuation relative to its expected earnings growth, while RGEN's PEG ratio is much higher at 4.76 [5] - HRMY's P/B ratio is 3.71, compared to RGEN's P/B of 4.70, suggesting HRMY is more attractively priced relative to its book value [6] Zacks Rank and Style Scores - HRMY holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while RGEN has a Zacks Rank of 3 (Hold) [3] - Based on the Style Scores system, HRMY has a Value grade of A, whereas RGEN has a Value grade of D, further supporting HRMY as the preferred choice for value investors [6]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) is a Pennsylvania based, commercial stage pharmaceutical company that it is best known for marketing and selling Wakix (p ...

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum and an improving earnings outlook [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Harmony Biosciences' earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, the earnings estimate is $0.73 per share, reflecting a +62.22% change from the previous year [4]. - The Zacks Consensus Estimate for the current quarter has increased by 5.49% over the last 30 days, with one estimate moving higher and no negative revisions [4]. - For the full year, the earnings estimate stands at $2.43 per share, representing a +14.08% change from the previous year [5]. - The consensus estimate for the current year has increased by 15.8%, with one estimate moving higher and no negative revisions [5]. Zacks Rank - The positive estimate revisions have led Harmony Biosciences to achieve a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [6]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [6]. Stock Performance - Harmony Biosciences shares have increased by 8.3% over the past four weeks, suggesting investor confidence in its earnings growth prospects [7].

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 8.3% over the past four weeks, closing at $36.42, with a mean price target of $50.80 indicating a potential upside of 39.5% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $13.43, where the lowest estimate is $28 (23.1% decline) and the highest is $75 (105.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 15.8% over the last 30 days [9][10] Group 2 - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [7] - While price targets may not be reliable indicators of actual price movements, they can provide a directional guide for potential stock performance [12]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positiv ...

Company Participation in Industry Events - Harmony Biosciences Holdings Inc will participate in the 43rd Annual J P Morgan Healthcare Conference in San Francisco CA on January 15 2025 [1] - Jeffrey M Dayno MD President and Chief Executive Officer is scheduled to present at the conference at 11:15 am PT 2:15 pm ET [1] - A webcast of the fireside chat will be available on the investor page of Harmony's website [1] Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases [2] - The company is driven by novel science visionary thinking and a commitment to addressing unmet medical needs [2] - Established by Paragon Biosciences LLC in 2017 and headquartered in Plymouth Meeting PA [2] - The company aims to create a better future through therapeutic innovations culture and community programs [2] Contact Information - Investor contact Brennan Doyle can be reached at 484-539-9700 or via email [3] - Media contact Cate McCanless can be reached at 202-641-6086 or via email [3]

PLYMOUTH MEETING, Pa., Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the "Selling Shareholders") at a public offering price of $31.00 per share. The Selling Shareholders have granted the under ...